|
C16ORF52 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.28785870856518E-14 |
| Normal-vs-Stage2 |
1.06800002175333E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.67110769666579E-12 |
| Stage1-vs-Stage2 |
8.490200E-01 |
| Stage1-vs-Stage3 |
4.615800E-03 |
| Stage1-vs-Stage4 |
6.979800E-03 |
| Stage2-vs-Stage3 |
6.697600E-02 |
| Stage2-vs-Stage4 |
3.109700E-02 |
| Stage3-vs-Stage4 |
6.139400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.16090000000535E-05 |
| Normal-vs-Asian |
2.33270003313635E-09 |
| Caucasian-vs-AfricanAmerican |
5.451600E-01 |
| Caucasian-vs-Asian |
4.821600E-01 |
| AfricanAmerican-vs-Asian |
8.449800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.430400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.86102261273891E-12 |
| Normal-vs-Age(41-60Yrs) |
1.4432899320127E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
2.44809999999651E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.205800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.428440E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.427400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.332600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.573000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.131000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.97590000000326E-05 |
| Classical-VS-Follicular |
5.872400E-01 |
| Classical-VS-Other |
3.954200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
3.351700E-04 |
| Tall-VS-Other |
1.398190E-01 |
| Tall-VS-Normal |
2.55351295663786E-15 |
| Follicular-VS-Other |
5.775400E-01 |
| Follicular-VS-Normal |
1.50930001829863E-09 |
| Other-VS-Normal |
3.016100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
5.42119682478415E-11 |
| N0-vs-N1 |
7.818800E-01 |
|
|
